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Abstract
Identifying individuals with hereditary cancer predisposition can improve health
outcomes for patients and their family members through early cancer detection and prevention
strategies. Prior research about family sharing of genetic test results among those with hereditary
breast cancer has overwhelmingly been limited to the BRCA1 and BRCA2 genes. The present
study sought to compare family sharing behaviors in women with pathogenic BRCA variants to
women with pathogenic variants in the more recently identified and characterized PALB2 gene.
A total of 18 BRCA carriers and 13 PALB2 carriers were interviewed about family sharing
practices using a semi-structured guide based on the Integrated Behavioral Model. Barriers and
facilitators to family sharing were similar for both BRCA and PALB2 carriers, with logistical
difficulties and emotional struggles related to anticipated negative reactions from relatives being
the most salient barriers. The most important facilitators were: attitude that sharing enables
health protection, provider recommendation, strong family relationships, confidence in sharing
basic information, knowledge of what to share and how to share, and belief that sharing is highly
important. Given similar attitudes, norms, and control beliefs related to family sharing, similar,
but tailored interventions may be effective at increasing family disclosures among both groups.
Such interventions should involve a discussion of patients’ attitudes towards sharing with
healthcare providers to strengthen motivations and address barriers and provision of
informational resources to increase confidence and knowledge. Family sharing resources should
clearly specify which relatives need to be informed, why sharing is important, and how at-risk
relatives may benefit.
v

Introduction
Breast cancer is the second most prevalent cancer in women with over 260,000 estimated
new cases in the United States in 2018 (Surveillance, Epidemiology, and End Results Program,
National Cancer Institute, 2018). Roughly 5-10% of female breast cancer patients have an
inherited predisposition, most commonly due to BRCA1 or BRCA2 (American Cancer Society,
2017). The lifetime risk to develop breast cancer for women with pathogenic BRCA variants is
60-70% (Kuchenbaecker et al., 2017), compared to a 12.4% lifetime risk for average women
(Surveillance, Epidemiology, and End Results Program, National Cancer Institute, 2018). In
addition to BRCA1 and BRCA2, there are other highly penetrant genes that also confer increased
risks for breast cancer. The gene PALB2 (partner and localizer of BRCA2) is estimated to account
for 1-3% of hereditary breast cancers (Antoniou et al., 2014; Casadei et al., 2011; Couch et al.,
2015; Cybulski et al., 2015; Thompson et al., 2016), with lifetime breast cancer risks ranging 3358%, modified by family history of breast cancer (Antoniou et al., 2014; Couch et al., 2017).
Next-generation sequencing and use of multi-gene panels has reduced costs and increased
efficiency of clinical genetic testing for hereditary breast cancer, thereby increasing identification
of high-risk individuals – particularly those with pathogenic variants in breast cancer genes
besides BRCA (Antoniou et al., 2014; Ricker et al., 2018). Identifying hereditary predisposition
to breast cancer is an important step for enabling early detection, prevention, and risk
management strategies and for guiding cancer treatment (Black, McClellan, Avard, & Knoppers,
2013; Katapodi, Northouse, Milliron, Liu, & Merajver, 2013; Ricker et al., 2018). Given the
higher risk and earlier onset of disease, women with pathogenic variants in BRCA1, BRCA2,
1

PALB2, and other breast cancer genes are eligible for increased surveillance and other preventive
measures starting at younger ages (Couch et al., 2017; Ricker et al., 2018). According to national
guidelines, high-risk screening and/or consideration of risk-reducing options may begin as early
as age 25 (sometimes younger) for BRCA carriers and age 30 (sometimes younger) for PALB2
carriers (National Comprehensive Cancer Network, 2018). High-risk screening can diagnose
breast cancer at an earlier, more treatable stage, thus prolonging survival, whereas prophylactic
mastectomy and salpingo-oophorectomy (when appropriate) can effectively reduce breast cancer
risks (Domchek et al., 2010; Lauby-Secretan et al., 2015; Nelson et al., 2014). For mutation
carriers who have already developed cancer, the benefit of identifying hereditary predisposition
is focused on preventing a second primary cancer and informing treatment decisions (Ricker et
al., 2018).
Identification of women with a cancer-predisposing variant confers health implications
for their family members, as well (McCarthy & Armstrong, 2014; Nelson et al., 2014). Relatives
of a BRCA or PALB2 carrier may have up to a 50% chance to harbor the same gene mutation and
associated cancer risks (Antoniou et al., 2014; Cheung, Olson, Yu, Han, & Beattie, 2010). For
this reason, women found to carry a pathogenic variant in one of these cancer-predisposing genes
are encouraged to notify their relatives of the result and the availability of genetic testing and risk
management (Dancyger, Smith, Jacobs, Wallace, & Michie, 2010). Relatives who choose to
pursue genetic testing for themselves may be able to clarify their own cancer risks and determine
optimal risk management strategies (Daly, Montgomery, Bingler, & Ruth, 2016; Fehniger, Lin,
Beattie, Joseph, & Kaplan, 2013; Katapodi et al., 2017). If relatives are determined to have
inherited cancer predisposition, they can then execute health protective behaviors that may
reduce breast cancer morbidity and mortality.
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Family sharing (also called family communication or intra-familial communication or
disclosure in the literature) is a complex yet critical step within the cancer control continuum
(Daly et al., 2016; Derbez, 2018; Division of Cancer Control and Population Sciences, National
Cancer Institute, 2017; Peters et al., 2011). Currently, it is the responsibility of the individual
tested to notify their relatives of any potential risks (Daly, 2015; Kardashian, Fehniger,
Creasman, Cheung, & Beattie, 2012). Studies have shown that rates of family sharing among
BRCA carriers are relatively high, ranging from approximately 73% to 96% (Daly et al., 2016;
Fehniger et al., 2013; Finlay et al., 2008; Hughes et al., 2002; Ricker et al., 2018). The most
important reasons cited for sharing genetic results include making relatives aware of risk,
suggesting they undergo genetic testing, and fulfilling a perceived responsibility to inform
(Hughes et al., 2002; McGivern et al., 2004). Seeking emotional support and advice about
management decisions have also been reported as motivators for sharing (Hamilton, Bowers, &
Williams, 2005; Hughes et al., 2002). Despite the importance of sharing, rates of disclosure
previously reported indicate that some at-risk relatives remain uninformed and unaware of
potential cancer risks (Black et al., 2013; Daly et al., 2016). Furthermore, testing rates among
family members remain low, ranging from roughly 15-50%, even when results are shared
(Blandy, Chabal, Stoppa-Lyonnet, & Julian-Reynier, 2003; Lieberman et al., 2018).
The relationship between family sharing and various individual, familial, and
sociocultural factors has been documented regarding disclosure of BRCA results (Nycum, Avard,
& Knoppers, 2009). Personal feelings and perceptions of risk, relatives’ attitudes, knowledge,
and finding “the right time” may impact the decision to share genetic results with family
members (Blandy et al., 2003; Cheung et al., 2010; Daly et al., 2016; Dean & Rauscher, 2018;
Derbez, 2018; Hamilton et al., 2005; Lafrenière, Bouchard, Godard, Simard, & Dorval, 2013;
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Lapointe et al., 2013; Nycum et al., 2009). Prior studies have shown that first-degree family
members are most likely to receive genetic risk information, suggesting that more distant family
members who may also beneﬁt are often excluded (Blandy et al., 2003; Elrick et al., 2017;
Kardashian et al., 2012; Katapodi et al., 2013; MacDonald et al., 2007; McGivern et al., 2004).
Family communication styles, traditions, religious beliefs, and norms have also been shown to
influence the decision to share (Etchegary, Potter, Perrier, & Wilson, 2013; Katapodi et al., 2013;
Koehly et al., 2009; Lafrenière et al., 2013; Peters et al., 2011). Minimal contact and/or
emotionally distant relationships with relatives have also been implicated as barriers to
disclosure of results (Daly et al., 2016; Elrick et al., 2017; Etchegary et al., 2013; Hughes et al.,
2002; Kardashian et al., 2012; MacDonald et al., 2007; McGivern et al., 2004). Those with a
strong family history of BRCA-related cancers are more likely to share compared to families with
a less striking history of cancer (Dean & Rauscher, 2018; Kardashian et al., 2012). Women are
more likely to communicate genetic information than men, and information is more often
communicated to female relatives and younger generations (Cheung et al., 2010; Elrick et al.,
2017; Etchegary et al., 2013; Finlay et al., 2008; Kardashian et al., 2012; MacDonald et al.,
2007; Patenaude et al., 2006; Vadaparampil, Malo, de la Cruz, & Christie, 2012).
Previous research about family sharing related to hereditary breast cancer has focused
almost exclusively on disclosure of BRCA1 and BRCA2 results (D’ Audiffret Van Haecke & de
Montgolfier, 2016; Ricker et al., 2018). Ricker et al. (2018) is the only published study to
explore family sharing among those with a gene mutation in other hereditary breast cancer genes
(though not exclusively hereditary breast cancer genes); however, they did not assess for barriers
and facilitators related to family sharing. Rather, a survey containing a combination of “yes/no”
and open-ended questions was utilized to measure rates of communication of genetic test results
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and family follow-up and a single Likert scale question was used to measure attitude about the
benefit of family sharing. PALB2 carriers were included in the Ricker et al. (2018) study, though
the number of PALB2 participants was not specified.
Given the limited data on family sharing and hereditary breast cancer beyond BRCA, the
present study sought to further our understanding of family sharing among women with
pathogenic PALB2 variants compared to women with pathogenic BRCA variants. It is unclear
whether different gene carriers experience unique barriers and facilitators with family sharing
and require different approaches to improve rates and quality of family sharing. Eliciting and
comparing disclosure behaviors in these two groups is therefore a critical first step in identifying
potentially modifiable factors that may serve as effective targets for interventions for PALB2
carriers, as well as assessing the applicability of BRCA–related interventions (Cheung et al.,
2010; Elrick et al., 2017). Addressing the most salient barriers and facilitators will be necessary
to increase rates of family sharing, enable more at-risk individuals to be proactive in cancer risk
management, and ensure that all have the opportunity to benefit from genetic testing. The current
study utilized qualitative methods to capture more in-depth and comprehensive data underlying
the motivators and barriers to family sharing, as this was not captured as part of the survey
conducted by Ricker et al. (2018) (Bradley, Curry, & Devers, 2007).
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Methods
Participants
Participants were recruited by a research team at Vanderbilt University from a group
consented to the GeneCARE study. GeneCARE participants were English-speaking females, 18
years or older, and living in the United States with a documented pathogenic/likely pathogenic
variant or variant of uncertain significance (VUS) in a gene associated with hereditary cancer.
The current study was limited to women enrolled in GeneCARE with a BRCA1, BRCA2, or
PALB2 pathogenic/likely pathogenic variant who indicated willingness to take part in an in-depth
telephone interview. All PALB2 carriers and a subset of BRCA carriers who met this criteria were
purposively selected for interviews in order to maximize diversity in family sharing and medical
management practices. We aimed to conduct 10 interviews for each carrier group according to
recommendations for achieving theoretical saturation, or the point at which no new themes are
emerging. Prior studies have found that small sample sizes ranging from 10 to 12 participants
can be sufficient for collecting most of the salient ideas and reaching saturation (Guest, Bunce, &
Johnson, 2006; Saunders et al., 2018; Weller et al., 2018). The study was approved by
Institutional Review Boards at Vanderbilt University and the University of South Florida.
Instrumentation
The study team developed a semi-structured interview guide (Appendix A) based on the
Integrated Behavioral Model (IBM) (Figure 1), which proposes that five main constructs directly
influence behavior and intention is the most important determinant (Montano & Kasprzyk,
1992). The IBM framework is an extension of the Theory of Planned Behavior (TPB), which has
6

been utilized in previous studies to understand family communication of genetic risk
(Montgomery et al., 2013; Wiens, Wilson, Honeywell, & Etchegary, 2013). Both theories state
that behavioral intention is the product of attitudinal, normative, and control beliefs; however,
the IBM incorporates knowledge and skills, salience, and environmental constraints as
behavioral modifiers. The IBM was chosen as the framework for this study as these additional
constructs may play an important role in the family sharing process.

Figure 1. The Integrated Behavioral Model.

An essential step in applying the IBM is conducting interviews with the population of
interest to elicit information about their beliefs (Montano & Kasprzyk, 1992). The interview
guide was designed to elicit seven IBM-related domains we thought would reveal underlying
differences and similarities in the family sharing behaviors of BRCA carriers and PALB2 carriers
(Table 1). These domains included: 1) attitudes, 2) normative influences, 3) perceived control
7

and environmental constraints, 4) self-efficacy, 5) knowledge and skills, 6) salience, and 7)
intention or decision.

Table 1. Targeted IBM-Related Constructs
Construct

Definition

Example Questions to Elicit
Construct
 How did you feel about the
idea of sharing your genetic
test result with family
members?
 Were there any benefits of
sharing?
 Were there any negative
effects of sharing?

Attitudes

Emotional response to the idea of
sharing, beliefs about the anticipated
or actual outcomes of sharing

Normative
Influences

Social pressures to share or not share 
results with family



Perceived Control
& Environmental
Constraints

How easy or difficult it is to share
test results with family and
environmental conditions that might
prevent sharing



Self-Efficacy

Confidence and effectiveness in
sharing








Knowledge &
Skills

Possessing the knowledge and skills
to communicate results to family
and convey the value of genetic
testing
8




Did a healthcare provider
encourage you to share your
result with family?
Who would support you
sharing your result?
Did some relatives not want to
hear about your result?
What made it easy for you to
share your genetic test result?
What made it hard for you to
share your genetic test result?
On a scale of 1-10, how
confident were you sharing
your result with family?
Which family members did
you feel most confident
sharing with?
What types of resources do
you think could be helpful?
Describe for me how you
shared you result with family?
What information did you tell
your family about your result?

Table 1 (continued)
Construct

Definition

Salience

Beliefs about how important it is
to share results

Intention or
Decision

Indication of readiness or
decision to share or not share
results with family

Example Questions to Elicit
Construct
 When someone tests positive for a
cancer gene mutation, on a scale of
1-10 how important is sharing that
result with family?




Which family members did you
talk to about your genetic test
result?
Do you intend to share your result
with this family member in the
future?
Did you tell any non-relatives
about your result?

Procedures
Baseline demographic and clinical data were available on all participants through
completion of the GeneCARE survey. Participants provided informed consent to the interview at
the time of enrollment in the survey portion of GeneCARE and consent was confirmed verbally
prior to audio-recording each respective interview. The semi-structured interview guide was used
to assess their initial reaction to their genetic test result, information about medical management
decisions (results of which are not within the scope of the current study), and what they
perceived to be facilitators and barriers to sharing their result with various family members. The
discussion focused on the at-risk side of the family, if that could be determined based on the
family history. Otherwise, both sides were considered at-risk and data for both sides of the
family were obtained. Each interview lasted approximately 30-60 minutes.
Interviews were conducted by 2 investigators trained in human subjects’ protection.
Audio recordings were transcribed verbatim and memos were created by the interviewer after
each interview to document important themes, memorable quotes, or striking observations.
9

Memos and transcripts of the first several interviews were analyzed to assess the need for
additional questions, revisions to the guide, and additional codes.
Data Analysis
A codebook was developed by three of the researchers based on the interview guide and a
single coder analyzed each transcript using RQDA qualitative data analysis software. Data
analysis utilized a thematic approach, with steps related to data immersion, generating codes, and
identifying, reviewing, and defining themes (Nowell, Norris, White, & Moules, 2017). Prior to
coding, transcripts from the first several interviews were reviewed in-depth in order to become
familiar with the data (Bradley et al., 2007). Transcripts were then coded line-by-line using
theory driven a priori codes and inductive, data-driven thematic codes developed through an
iterative process (Tracy, 2012; Tracy & Hinrichs, 2017).
The following codes were added during initial analysis of the interview transcripts:
ATT_fam positive; ATT_fam negative, ATT_fam other; KNOW_information; and DEC_not
shared non-family. Furthermore, the following codes were anticipated but subsequently deleted
from the codebook after initial analysis: ATT_ignore; KNOW_risks to family; and KNOW_risks
and benefits. All transcripts were then re-analyzed to ensure that a priori and data-driven codes
were utilized appropriately. Interviews were classified using a total of 31 codes within seven
theoretical constructs. The final codebook can be found in Appendix B.
Through coding, sorting, and review of the data, the most salient themes regarding family
sharing were identified and interpreted in the context of the IBM framework. Particular attention
was paid to items mentioned in one carrier group, but not the other. Illustrative quotes were
selected to accompany each theme related to factors that facilitate or inhibit sharing of genetic
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test results with family members. Demographic and clinical characteristics of the study
participants were summarized using descriptive statistics.
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Results
Participant Characteristics
A total of 168 BRCA carriers and 22 PALB2 carriers who completed the GeneCARE
survey expressed interest in participating in the in-depth interviews. Eighteen BRCA carriers and
thirteen PALB2 carriers were ultimately interviewed for this study. Additional participants were
recruited beyond the original target sample size to ensure that at least ten interviews for each
group were completed. These additional participants were recruited using the same methods
discussed previously.
Participant demographic and clinical characteristics are shown in Table 2. BRCA carriers
and PALB2 carriers had a mean age of 53.67 and 55.62 years, respectively. The majority of
carriers in both groups self-identified as Non-Hispanic White. Most of the BRCA participants and
all of the PALB2 participants reported themselves as college graduates. Approximately 72% of
the BRCA carriers and 85% of the PALB2 carriers reported having private insurance. 13 BRCA
carriers and nearly all PALB2 carriers had a personal history of cancer. While almost all PALB2
participants were the first member of their family to be genetically tested, the majority of BRCA
carriers were uncertain if other relatives had tested first.
Themes Related to Family Sharing
In-depth interviews with BRCA carriers and PALB2 carriers revealed twelve major
themes related to family sharing. Themes were organized into seven IBM-related theoretical
constructs and are described according to construct in detail below. The following themes
emerged within the ‘attitudes’ construct: health protection, anticipated negative emotions from
12

Table 2. Participant Demographics

Age, years
Mean (Range)
Race/Ethnicity, n (%)
NHW
Black
Hispanic
Highest Completed Education, n (%)
≤ 12th grade/GED
Vocational School/Some College
College Graduate
Other
Insurance, n (%)
Private
Military/Veteran
Medicare
Medicaid
Personal History of Cancer, n (%)
None
Breast
Breast and Ovarian
First Family Member Tested, n (%)
No
Yes
Unknown

BRCA1/2
n = 18

PALB2
n = 13

53.67 (30 – 71)

55.62 (39 – 69)

8 (44.4)
4 (22.2)
6 (33.3)

12 (92.3)
1 (7.7)
0

2 (11.1)
3 (16.7)
13 (72.2)
0

0
0
13 (100)
0

13 (72.2)
2 (11.1)
2 (11.1)
1 (5.6)

11 (84.6)
1 (7.7)
1 (7.7)
0

5 (27.8)
12 (66.7)
1 (5.6)

1 (7.7)
12 (92.3)
0

1 (5.6)
4 (22.2)
13 (72.2)

1 (7.7)
12 (92.3)
0

family members, and family reactions range from supportive to not supportive. The ‘perceived
norms’ construct revealed normative influence from providers and family. Themes within the
‘perceived control and environmental constraints’ construct included strong family relationships,
lack of contact and communication barriers, and impact of public knowledge and awareness of
BRCA. Themes related to the ‘self-efficacy’ construct were confidence in sharing basics and
informational resources boost self-efficacy. In terms of knowledge and skills, participants knew
what to share and how to share. The ‘salience’ construct revealed the theme that sharing is
important when risks are high, actionable and the relative is prepared. Finally, the ‘intention and
decision’ construct showed high rates of sharing and intention to share.
13

Attitudes
Participant attitudes towards family sharing were divided into positive and negative
attitudes. Both BRCA and PALB2 carriers felt strongly that sharing their positive genetic test
result would protect the health of their family members via follow-up genetic testing and/or
increased cancer surveillance. Both groups frequently quoted the saying “knowledge is power”
to succinctly describe why they felt positively about sharing. It was apparent that participants
viewed sharing as a way to protect not only their living relatives, but also future generations.

Table 3. Theme: Health Protection
Brief description
Participants felt that sharing
would allow relatives to be
proactive in their own
cancer risk management

Illustrative quotes
“I think information is power, because once you have the
information you can make better decisions. So I wanted them to
have the necessary information for them to make decisions for
themselves and their families.” (PALB2 carrier, age 63)
“I wanted to make sure if anybody out there has the gene, they
needed to know about it so they could take whatever
precautions were necessary so that they didn’t get breast cancer.
I felt sort of empowered to get this information to them and
make sure that they protected their health.” (PALB2 carrier, age
60)
“I feel like that if you know your chances are better to get
cancer, then you can do something about it before it happens.”
(BRCA carrier, age 69)
“I wanted them to know so that they have the option of testing.
That they would know it is available and make the decision… if
you just don’t know that you have it, things can happen in the
future, and if you do know then you can do stuff to prevent it.”
(BRCA carrier, age 71)

Women in both the BRCA and PALB2 groups were concerned about how their family
members might respond when learning about their positive genetic test result. The two groups
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acknowledged that sharing may cause family members to experience a variety of negative
emotions, including fear, worry, distress, and guilt for having passed down the mutation. A few
participants were uncertain if their family members would have access to knowledgeable
providers or recommended follow-up care after learning about their risk. Interestingly, only a
single participant in each carrier group was hesitant to share their result with family due to
concerns for privacy.

Table 4. Theme: Anticipated Negative Emotions from Family Members
Brief description
Participants felt that sharing their
result could cause family members
to feel scared, worried, and
overwhelmed

Illustrative quotes
“I was concerned because, like I said, I know it’s going
to be stressful for them. They’re going to have to make
their decision as to what they want to do with this
information.” (PALB2 carrier, age 57)
“I was sad, and then obviously people I told are gonna
be sad…it’s a scary thing to learn, to know you could
carry this gene.” (PALB2 carrier, age 49)
“Fearful of putting an element of fear about that person’s
health in their head. You know, possibly making them
fearful of dying from ovarian cancer more so than breast
cancer.” (BRCA carrier, age 52)
“If my mother were still alive I may have been more
hesitant for her to know because I would think, knowing
her personality, she would feel guilty for having passed
this along to us.” (BRCA carrier, age 59)

Despite participants’ concerns about negative emotional reactions, participants found that
many family members reacted positively when learning about the positive genetic test result.
Relatives were reported as being supportive, grateful, receptive, and not surprised by the
information. Nonetheless, some family members did not show interest in learning about the test
result and, as anticipated by participants, certain relatives became worried or scared. Several
15

family members reportedly ignored the information. Multiple BRCA carriers stated their family
members were in denial, confused, or did not fully understand the result.

Table 5. Theme: Family Reactions Range from Supportive to Not Supportive
Brief description
The reactions of family
members ranged from
positive/supportive to
negative/not supportive

Illustrative quotes
“I had one uncle who said, “You are very brave.” I didn’t get
any negative. I only got positive, “Yeah thanks for letting us
know” kind of thing.” (PALB2 carrier, age 63).
“I don’t think they were that surprised, because like I said, the
breast cancer has been running in the family, and my sister
had the ovarian cancer, so it wasn’t like totally out of the
blue.” (PALB2 carrier, age 57)
“One of my sisters told me to mind my own business. Her
health is her prerogative, and I should mind my own business.
That was very unexpected.” (PALB2 carrier, age 59)
“Two out of three [siblings] were glad. One wasn’t…she was
more like, “I wish I didn’t know.” (PALB2 carrier, age 60)
“I think my sisters were more supportive, because they have
daughters too, and the breast cancer runs in women more so
my sisters were probably the most supportive and the most
interested in it.” (BRCA carrier, age 64)
“A lot of them were happy that they were given the
information, but it was one of those things, “thanks for giving
me the information” but they didn’t really follow up on it.”
(BRCA carrier, age 49)
“Well, with my sister she just said…”I’m not doing this, I’m
not dealing with this, if I’m meant to die from breast cancer or
ovarian cancer then I will.” (BRCA carrier, age 52)
“His attitude is kinda like, it doesn’t affect me right now, I
don’t really care. But he’s also, he’s very much one to be in
denial and that’s his personality. He’d rather not know the “I
don’t have to think about it” kind of thing.” (BRCA carrier,
age 59)
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Normative Influence
Healthcare providers had the most significant normative influence for participants with
regards to family sharing. The majority of these providers were genetic counselors, but other
genetics professionals (e.g. geneticist, genetics nurse), oncologists, and surgeons were also
mentioned as encouraging family sharing as part of recommended follow-up. All but a few
participants recalled a specific conversation when their provider encouraged them to share their
result with close and extended relatives on the at-risk side of the family, if that could be
determined. In terms of familial influence, most participants expected their family members
would want to know about their positive genetic test result. However, participants in both groups
expressed concerns that certain family members would not be receptive to this information or
they would not understand the significance. Only one PALB2 participant (age 65) mentioned her
religious upbringing and “Catholic guilt” as a source of pressure to share.

Table 6. Theme: Normative Influence from Providers and Family
Brief description
Most participants were
encouraged by a healthcare
provider to share their positive
genetic test result with at-risk
relatives.

Illustrative quotes
[Were there any recommendations the genetic counselor gave
you that you hadn’t done at this point?] “Yeah, there was
nothing else for me to do outside of just talk with your
family, just to let them know, to share what my diagnosis
[test result] was.” (PALB2 carrier, age 49)
[What were some of the things that your breast surgeon told
you to do because you have this BRCA result?] “First thing
was to get the other breast removed…second thing was to get
my ovaries removed…and then tell like my family, so that
they can also get tested.” (BRCA carrier, age 60)

Many participants felt their
families would be supportive
of sharing, though some
expected their families would
not be supportive.

“I pretty much knew my cousins that I shared it with, that
they would appreciate it, so I didn’t feel like I was telling
them anything they would not appreciate knowing.” (PALB2
carrier, age 69)
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Table 6 (continued)
Brief description
Many participants felt their
families would be supportive
of sharing, though some
expected their families would
not be supportive.

Illustrative quotes
“I knew they were gonna be supportive. I knew nobody was
gonna question my decision. I didn’t feel anybody was gonna
not believe me. They’re a very rational, reasonable,
supportive bunch of people. So I just knew I could share it
with them.” (PALB2 carrier, age 60)
“I’m afraid though, because I feel like they might be the type
to say, “What is that? Mind your own business.”” (PALB2
carrier, age 59)
“[My sister-in-law] had asked me to do genetic testing. They
were waiting for results to see if my brother should get
tested.” (BRCA carrier, age 64)
“I would like to sit down with her [niece] and talk to her
about it but other family members say, “No, don’t.” There’s a
divide in the family…because she’s getting married next year
and it might make her feel less of…that she might feel like
damage goods.” (BRCA carrier, 59)
“I didn’t expect much a reaction from them. They didn’t have
much of a reaction…when it comes to cancer we all kind of
share anyway.” (BRCA carrier, age 38)

Perceived Control and Environmental Constraints
When asked specifically about what made it easier to share genetic results with family,
participants in both the BRCA and PALB2 groups endorsed strong familial relationships. Open
family communication styles and frequent contact made the task of sharing less daunting and
more convenient. Additionally, it was helpful if relatives had prior knowledge of a participant’s
personal cancer diagnosis and/or the family history of cancer. Help from other family members
by communicating to other relatives, sharing contact information, or even initiating the sharing
process made it easier for many participants.
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Table 7. Theme: Strong Family Relationships
Brief description
Participants with strong
family ties found it
easier to share their
result with at-risk
relatives

Illustrative quotes
“I was very open with my family about everything, my treatments
and everything, so they were already aware of what I was going
through and what I was having done. So, I guess that made it easier
because it wasn’t like I was calling them out of the blue and telling
them that I have this. They already knew.” (PALB2 carrier, age 51)
“We’re a pretty close bunch, so I had full access to them… there’s
definitely open lines of communication.” (BRCA carrier, age 49)
“My dad has some nieces that we don’t talk to directly but we
know how to get ahold of them indirectly through mutual family
members and friends.” (BRCA carrier, age 52)

Conversely, participants in both groups felt that distant relationships with relatives and
difficulty contacting family members made it harder to share. A BRCA carrier mentioned it was
difficult for her to share with her family members in a different country due to lack of resources
in their native language. Only a single participant in the PALB2 group cited relatives’ education
level as a source of hardship in sharing.

Table 8. Theme: Lack of Contact and Communication Barriers
Brief description
Participants had to overcome
estranged relationships and
communication barriers to share
with certain at-risk relatives.

Illustrative quotes
“Everything was difficult. I had to find them… because
you lose touch with people.” (PALB2 carrier, age 65)
“I don’t communicate with them very often, so it’s not
like it was purposely done. It just didn’t happen.”
(PALB2 carrier, age 48)
“I’m just not that close with them… we just don’t see
each other that often and we don’t really share
information that personal.” (BRCA carrier, age 30)
“The problem is that a lot of the information is English
and not all of them speak English, so that made it a
little bit harder.” (BRCA carrier, age 46)
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Of note, publicity and awareness of the BRCA genes was mentioned by participants in
each group as impacting family sharing, but for different reasons. One BRCA carrier felt the
publicity from celebrity disclosures, specifically Angelina Jolie, made sharing with family easier.
Similarly, a PALB2 participant (age 48) used the BRCA gene as an example when describing
PALB2 to family members. She stated, “I told them the type of genetic mutation it was and what
I understood, [and] how it related to BRCA.” A different PALB2 carrier (age 59) felt that
awareness of BRCA actually made non-relatives that she shared with less sympathetic: “They’re
like, “It’s not BRCA.” I mean they believe me, but it’s just not known. They probably just think,
“Oh, you don’t have the real gene, cause you don’t have BRCA.” Fortunately, this participant
said that her family members felt differently about PALB2, and “figured whatever it was, it was
bad and important.”

Table 9. Theme: Impact of Public Knowledge and Awareness of BRCA
Brief description
Participants felt that
awareness of BRCA
among the public
impacted the sharing
process.

Illustrative quotes
“Having it be PALB2 makes me feel like lesser than, like it’s not a
real risk…Even in my own mind, it’s not BRCA, it’s a smaller risk,
even though I have evidence that it’s very active in my family.
Then how I feel others just discount me so much, because it’s not
BRCA. Even people who know, but not my family, but people who
know. Even doctors, I feel like just really discount the risk, cause
it’s not BRCA.” (PALB2 carrier, age 59)
“Because that [Angelina Jolie BRCA disclosure] was in the news,
they understood, there was no explaining or anything. They got it.”
(BRCA carrier, age 60)

Self-Efficacy
Overall, participants in the BRCA group and the PALB2 group felt confident in their
ability to effectively share with family members. Participants felt most confident communicating
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with their close female relatives, such as sisters, mothers, and cousins. Some participants felt less
confident because they “didn’t know everything” or were unable to answer all of their family
members’ questions. On the other hand, one BRCA carrier (age 37) with a background in
genetics felt especially confident talking to her family about her result, saying, “I think just
having a background in genetics made it easier for me, both in that I had a better understanding
of it and also because people trusted me more.”

Table 10. Theme: Confident in Sharing Basics
Brief description
Participants felt very confident
sharing their test result with atrisk relatives, but less confident
answering subsequent questions.

Illustrative quotes
“I wasn’t worried about it, I wasn’t insecure about it, I
wasn’t not confident that I understood it. I felt I knew
enough to share it intelligently.” (PALB2 carrier, age 54)
“There’s a lot of questions that I didn’t know the answer
to and even my doctor didn’t. Because again, five years
ago they really didn’t have a lot of information about the
PALB2 gene.” (PALB2 carrier, age 49)
“I felt confident about it because I had it done after my
cancer diagnosis and my sister had already had it done. I
kind of had an inkling that I would be positive with that,
so we talked about it among ourselves, my sisters and I.”
(BRCA carrier, age 60)
“Well I don’t have all the answers, you know. There’s a
lot of questions… there’s a lot of things I didn’t know.”
(BRCA carrier, age 64)

Confidence was bolstered by written information about their gene mutation and the
associated risks from a provider or even the genetic testing laboratory. While the majority of
women in both groups were offered resources to aid disclosures, roughly 1/3 of participants did
not report receiving materials. Several PALB2 carriers found that the family letter from their
provider (most often a genetic counselor) made sharing accurate information much easier. One
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BRCA participant watched videos prior to genetic counseling, and thought that alternatives to
printed handouts could be beneficial for sharing, too. When asked what other resources may be
helpful with family sharing, both the BRCA and PALB2 groups suggested a handout containing
information on why sharing is important and a short script of what to say and additional online
resources for gathering more information. When asked if having a healthcare provider disclose
results would help participants feel more efficacious about sharing, there were mixed feelings in
both groups for fear of bombarding relatives without notice or the disclosure being too
impersonal. Though, one BRCA carrier (age 52) mentioned her sister would “take it more
seriously” coming from a healthcare provider.

Table 11. Theme: Informational Resources Boost Self-Efficacy
Brief description
Participants feel more
confident when given
resources about their gene
mutation and the associated
risks to use for sharing.

Illustrative quotes
“I would say perhaps when you receive the information from
the geneticist, maybe a little script from the geneticist on,
“Here’s why it’s important to share with your family members.
Here’s some talking points. Here’s some nice ways to deliver
it.” Maybe that would’ve been a nice thing to have in your
back pocket when you’re going out to share this information.”
(PALB2 carrier, age 60)
“Well, I think having that letter, and even recently my younger
brother said, “I need to get that stuff done.” So I scanned my
letter and resent it to him. I think having that written
information is very, very helpful.” (PALB2 carrier, age 63)
“With the letter, more confident, because here’s what I got,
here’s the results, here’s a copy. It helped versus just telling
someone because I think people believe, whether it’s right or
wrong, if they have something in print and shows research and
shows the lab and shows whatever, I think they’re more likely
to believe it.” (PALB2 carrier, age 60)
“Maybe some more links of like websites to visit, that would
have given me more information to look on my own. You
know, like reputable ones.” (PALB2 carrier, age 39)
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Table 11 (continued)
Brief description
Participants feel more
confident when given
resources about their gene
mutation and the associated
risks to use for sharing.

Illustrative quotes
“Maybe if there’s some type of short, little animated
something, not so serious, comic or something, they could see
on the social media because especially young people, that’s
where everyone is.” (BRCA carrier, age 38)
“I was especially [confident] with the information that I got
straight from the testing company because that made it so
much easier. I mean it was detailed and it was really good
information, so if I had to do it myself it would be hard to
explain it to them…it also probably showed them how serious
it was because it wasn’t just coming from me.” (BRCA carrier,
age 60)
“Maybe a brochure that gives you helpful hints on how to
share.” (BRCA carrier, age 52)
“So when I had my genetic testing they sent me a video…I
thought that was really interesting to me even though I felt like
I already had a good understanding it still was interesting to
watch, but I feel like for people who didn’t have as good of an
understanding I thought that was really helpful.” (BRCA
carrier, age 37)

Participants were asked to offer advice or suggestions to other patients considering
sharing a test result with family. Both groups recommended sharing simple information with atrisk relatives. Collectively, they would encourage others to research and prepare before sharing
and send resources to family members afterwards. Both groups stressed focusing on facts rather
than emotions, and if conflicted about sharing, considering which family members need to know
and why.
Knowledge and Skills
Participants were well-informed about which family members were at-risk and utilized a
variety of methods to disclose their positive result. Many participants shared in-person, either in
an individual or group setting, or via phone, text, email, or social media. Both groups frequently
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enlisted the help of other family members to ensure that all at-risk relatives were contacted.
Many participants provided or at least offered their family members resources to supplement the
initial conversation. Interestingly, more PALB2 carriers compared to BRCA carriers utilized a
family sharing letter from their provider to disseminate the information. The information
communicated to relatives was fairly consistent between the two groups, focusing on the cancer
gene involved, associated risks, heritability, and availability of genetic testing and follow-up care
options. PALB2 carriers consistently mentioned breast and pancreatic cancer risks when recalling
their conversations with family members, however there was variability in reporting ovarian
cancer risk.

Table 12. Theme: Knowing What to Share and How to Share
Brief description
Participants demonstrated
strong knowledge of methods
for sharing and relevant
information to provide when
sharing their test result.

Illustrative quotes
“So what I decided to do on my own was make a list of
paternal cousins and send out letter letting them know what
had happened with our family, and then sent them a little
information on PALB2 – not a lot to overwhelm.” (PALB2
carrier, age 65)
“I doubt I told any in person, initially…I probably sent out a
group text or something.” (PALB2 carrier, age 39)
“I said, “I had the genetic testing. I do carry the PALB2
gene. After mom was tested, it confirmed which side of the
family the PALB2 gene comes from, what the result is, it is
higher probability of beast and pancreatic cancer and just
you should be aware of that. You should get tested if you’re
interested.” And that’s how I put it.” (PALB2 carrier, age 60)
“I mean because some people have said they sent letters to
their family members and stuff like that. I mean I would
have never dreamed of doing that. You know, I called
everybody.” (BRCA carrier, age 64)
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Table 12 (continued)
Brief description
Participants demonstrated
strong knowledge of methods
for sharing and relevant
information to provide when
sharing their test result.

Illustrative quotes
“We had a big, not a big, but my dad, his 80th birthday was
a few weeks ago, and yeah, everybody now in my family,
which most of them I hadn’t seen for several years, but they
all know now.” (BRCA carrier, age 52)
“I talked to them about it and told them basically passed on
all of the information and the chances that they might have
it… I told them about their increased chances of the certain
types of cancer. I told them I had the documentation if
they’d like to see it.” (BRCA carrier, age 59)

Salience
Both the BRCA and PALB2 groups felt that family sharing was highly important because
it enabled family members to take appropriate actions. Many admitted they would want this
information from another family member who tested positive. Multiple participants in each
group cautioned that there are circumstances in which sharing may be less important, for
example if the recipient is not prepared to learn of the risk or is expected to react poorly based on
their personality or past behaviors. Nonetheless, participants who anticipated or experienced a
negative reaction from a family member stated they would still share despite the perceived or
actual negative outcome. One PALB2 participant (age 69) shared, “I felt like if I had angered her
or made her upset, then she wasn’t thinking in her best interest, and that wasn’t going to stop me
[from sharing].”
Surprisingly, participants in each group explained that the importance of sharing with
family was somewhat dependent on our understanding of the gene’s penetrance and associated
risks. Specifically for PALB2, one participant explained that as the gene became more
understood and the management recommendations changed, sharing became more important.
Participants in both groups admitted having perceptions that female relatives were at greater risk
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given the associated cancer risks compared to male relatives, but acknowledged that both women
and men could be carriers of the familial variant.

Table 13. Theme: Important When Risks Are High, Actionable and Relative is Prepared
Brief description
Participants felt that sharing a
positive genetic test result is
important in most situations.

Illustrative quotes
“It’s important. People need to know what they’re up
against. If you don’t know what your history is, your
medical history is, how can you counteract it? How can you
start making changes as early as you possibly can to thwart
off any possible disease inflicting you.” (PALB2 carrier, age
49)
“I felt like it was information that I didn’t have before that
was very important to share.” (PALB2 carrier, age 69)
“I think it’s very important because then I at least have the
knowledge and then I can do with it what I want… I might
have been really upset if a couple of my cousins hadn’t
shared this and then all of a sudden I got breast cancer.”
(BRCA carrier, age 64)
“I think it’s probably most important if it affects their health
perspective, but if it’s just mostly about you sharing
information about your own health, I don’t think it’s
important. I mean, if we’re talking about you find out that
you have a mutation that they might have too, then I guess
I’d say it’s more [important].” (BRCA carrier, age 30)

Participants felt that sharing a
positive genetic test result is
less important if family
members cannot handle
knowing.

“You have to know the people that you’re going to be
telling and come up with an idea of, “Should I do this or
not?”… You have to weigh the pluses and the minuses of
telling them or not telling them.” (PALB2 carrier, age 57)
“It’s important to share it…it’s important to share it with the
ones you want to share it with, if there was a reason why.
Let’s say it was not going to be a good idea to tell someone
because of their particular state of mind or health or
something, then of course it’s not going to be necessary.”
(PALB2 carrier, age 48)
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Table 13 (continued)
Brief description
Participants felt that sharing a
positive genetic test result is
less important if family
members cannot handle
knowing.

Illustrative quotes
“It depends on how close you are with them and just how
much information they really need to know. Like I said,
some people can’t handle it for the fact that they may not
understand everything that you are talking about.” (BRCA
carrier, age 60)

Participants felt that sharing a
positive genetic test result is
more important when there are
high risks and relatives can
take action, especially females.

[On a scale of 1 to 10, how important is sharing your result
with family?] “When I first got diagnosed and they said, “Oh
we don’t know much about PALB2,” I would have said
maybe like a 3 or 4. Now that I think the standard of care is
if you have the PALB2 you do get a mastectomy right away
and you’re put on high alert, that’s a lot different than what
we talked about in 2015.” (PALB2 carrier, age 54)
“I think maybe if they would have been female, I don’t know
why, but I would have been more praying to maybe tell
them, because of the breast and ovarian aspect.” (PALB2
carrier, age 57)
“I think it’s mostly just how it affects their health, and I
guess how severe your mutation is, whether it’s something
that carries a higher risk of having a disease or if it’s like,
“No, you’re definitely gonna get it.” (BRCA carrier, age 30)
“In my mind, she’s the only one [at risk], it’s not true that it
only affects her but it affects her more because she’s
female.” (BRCA carrier, age 55)

Intention and Decision
Participants reported sharing their result among various first-, second-, and third-degree
relatives on the at-risk side of their family (if known), otherwise both sides of their family.
Immediate family members, including children, siblings, and parents, were consistently
informed, whereas nieces, nephews, aunts, uncles, and cousins were not always contacted. For
both the BRCA and PALB2 groups, family members that were not directly contacted by the
participant were often informed by a different family member. Young children were usually not
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informed of the positive genetic test result, though participants expressed intention to share with
them in the future. Participants did not want to burden their children with this information and
felt it would be better to wait until the information could be fully understood and used for
medical decision-making.
Overall, participants were very satisfied with their decision to share their result with
family members. Several participants expressed frustration, though, due to lack of follow-up
among their family members. While reflecting on her decision to share, one BRCA carrier (age
52) felt “completely satisfied with [my decision], completely unsatisfied with their reactions. All
of them.” Participants in both groups said that financial issues, competing life demands,
perceived lack of relevance, and preference towards not knowing their carrier status were
frequent barriers that family members faced related to genetic testing. Some participants
expressed that sharing may need to be an on-going conversation to ensure appropriate family
follow-up.
Results were frequently shared with non-family members, such as friends, support
groups, co-workers, and spouses. Similar to their attitudes with family members, participants
reported sharing with non-relatives to increase awareness of genetic testing and the importance
of screenings, like mammograms, provide life updates, and receive support. Many participants
were prompted to share their result with non-relatives when the topic came up in conversation. A
PALB2 carrier (age 51) said, “I didn’t bring it up unless it was something that somebody asked
me about or whatever. But I’m not the kind of person to hide things, so if somebody asked me
something I’d tell them.” When asked about disclosing to co-workers, a few participants
preferred to keep their private and professional lives separate, thus chose not to share in work
settings.
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Table 14. Theme: High Rates of Sharing and Intention to Share
Brief description
Participants reported
sharing (directly or
indirectly) or intending to
share with the majority of
their at-risk relatives.

Illustrative quotes
“I knew that my mom had talked to her brother about it and
then he talked to his sons. So that took care of that family. My
mom had another sister that she wasn’t really in touch with, but
I think her brother ended up talking to the sister. I didn’t really
feel the need to share the news with anyone.” (BRCA carrier,
age 30)
“I think that when he’s a little bit older I’m going to suggest
that, you remember how I had cancer, and that you might
wanna ask your doctor about getting tested for this just to see if
you have it.” (BRCA carrier, age 52)
“I would say 18, but I would probably push it out. So maybe
out of college or something when he’s starting to actually get a
life and get things settled for himself.” (PALB2 carrier, age 39)

Participants reported
sharing with non-family
members, such as friends,
coworkers, and support
groups.

“I’ve told most of my friends about it. and because I think it’s
very important for people to know even if they’re not facing it,
that maybe they know somebody else who should be tested or
whatever and every time I hear about somebody whose parent
had pancreatic cancer or whose had ovarian cancer, my first
question is have they ever been tested? Have you ever been
genetically tested?” (BRCA carrier, age 59)
“They’re friends, people who I care about and who care about
me and wanted to know what was happening with my diagnosis
and all the things that went along with it like this…people
wanted to be informed and involved and so I informed them
and I involved them” (PALB2 carrier, age 48)

Barriers and Facilitators to Family Sharing
The major themes identified through in-depth interviewing with BRCA and PALB2
carriers served as barriers and facilitators to family sharing. Facilitators, or factors that promoted
family sharing, included the following themes: health protection; normative influence from
providers; strong family relationships; and high confidence, knowledge, and salience. Barriers,
or factors that inhibited family sharing, included the themes anticipated negative emotions from
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family members and lack of contact and communication barriers. The remaining themes were
endorsed as both promoting and inhibiting sharing, thus could not be discretely assigned as a
facilitator or barrier to sharing.

30

Discussion
Our findings suggest that women with a pathogenic BRCA variant or PALB2 variant
experience similar barriers and facilitators when disclosing a positive genetic test result to at-risk
relatives and may benefit from similar interventions to improve rates and quality of family
sharing. To our knowledge, this is among the first studies to qualitatively examine barriers and
facilitators outside the realm of BRCA-related test results, thus adding to the literature on family
sharing in other hereditary breast cancer genes. According to the Integrated Behavioral Model
(IBM), participants’ attitudes, normative influences, and personal control beliefs served as
barriers and facilitators that influenced their motivation to share and, in combination with other
factors, their ultimate decision to share. These findings applied to the IBM framework are shown
in Figure 2. It seems that facilitating factors outweighed barriers to sharing, which enabled the
high rates of disclosures reported by this sample.

Figure 2. Family Sharing for BRCA and PALB2 Carriers Using IBM Framework.
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Theme: Health Protection
Participants in both the BRCA and PALB2 carrier groups reported similar facilitators to
family sharing, most importantly the attitude that disclosing to at-risk relatives enables health
protective behaviors. This theme is consistent with previous studies that have found the most
salient motivators for sharing were to make relatives aware of possible risks and enable
appropriate follow-up care (Hughes et al., 2002; McGivern et al., 2004). A more recent study by
Ricker et al. (2018) similarly found that both high- and moderate-penetrance gene carriers agreed
that family sharing is important for facilitating early detection and prevention strategies among
at-risk relatives. Although previously reported in the literature, sharing for the purpose of
receiving emotional support and advice was not a primary motivator among this sample
(Hamilton et al., 2005; Hughes et al., 2002). Many participants already felt supported and
informed, so they were not motivated to share for these reasons.
Theme: Anticipated Negative Emotions from Family Members
Women with BRCA variants or PALB2 variants had similar concerns about family
sharing, particularly related to how family members would respond. Although this did not keep
participants in this study from sharing, the majority of women in both groups felt that disclosing
their positive genetic result might cause certain family members to feel fear, worry, distress, and
even guilt. Other studies have similarly found that individuals are less likely to share if they
anticipate family members reacting poorly (Derbez, 2018; Forrest K et al., 2003; Hamilton et al.,
2005; Lafrenière et al., 2013). It appears that this barrier can be overcome, as observed in this
sample, when individuals are sufficiently motivated by other factors, such perceived benefits,
importance, confidence, and ease of sharing.
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Theme: Family Reactions Range from Supportive to Not Supportive
Family reactions have been reported as ranging from interest to disinterest (Gaff, Collins,
Symes, & Halliday, 2005). For the most part, family members in this study were reported as
responding positively during family sharing (e.g. supportive, grateful, receptive, not surprised) or
indifferent to the news. Individuals in the position to disclose a positive genetic test result to
family may find relief in knowing that family members are often receptive during family sharing,
even if they do not act upon the information provided; however, individuals should be prepared
for any relatives that may react negatively.
Theme: Normative Influence from Providers and Family
Encouragement from healthcare providers to share genetic test results was the most
consistent source of normative influence among both BRCA and PALB2 carriers, as expected
support from family members was variable. As discussed in Black et al. (2013), healthcare
professionals have an important role in initiating the family sharing process and identifying all
at-risk relatives. Providers are especially important for helping patients understand the
significance of sharing with their more extended relatives. The pre-test counseling session has
been viewed as an advantageous opportunity to introduce the idea of family sharing, though ongoing support after the pre-test meeting is important for patient follow-through (D’ Audiffret
Van Haecke & de Montgolfier, 2016). Although a few participants could not recall a specific
conversation, they all reported that their provider(s) presumably encouraged them to notify
family.
Theme: Strong Family Relationships
Women in both carrier groups felt that strong relationships with their families made it
easier to share their positive genetic test result. Participants who communicated with relatives
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frequently and openly found it easier to disclose this information, even more so if the family
members had known about the participant’s cancer diagnosis and/or the family history. Family
communication styles, norms, and awareness have been shown to influence willingness to share
(Dean & Rauscher, 2018; Etchegary et al., 2013; Kardashian et al., 2012; Katapodi et al., 2013;
Koehly et al., 2009; Lafrenière et al., 2013; Peters et al., 2011). Strong family relationships were
also exhibited via relatives’ willingness to help with the disclosure process. The significance of
involving other family members in the sharing process has been described (Koehly et al., 2009).
Theme: Lack of Contact and Communication Barriers
BRCA and PALB2 participants both cited distant relationships and logistical struggles as
factors that made sharing their positive test result with at-risk relatives more difficult. Minimal
contact due to emotionally distant relationships with relatives has been reported as a barrier to
family sharing frequently in the literature (Daly et al., 2016; Elrick et al., 2017; Etchegary et al.,
2013; Hughes et al., 2002; Kardashian et al., 2012; MacDonald et al., 2007; McGivern et al.,
2004). While many participants were able to overcome logistical hurdles, like trouble obtaining
contact information or actually making contact, some BRCA and PALB2 carriers did not and
ended up not disclosing to all at-risk relatives. As reported in other studies, these communication
barriers frequently inhibit family sharing, even if non-communication is unintentional (Nycum et
al., 2009).
Theme: Impact of Public Knowledge and Awareness of BRCA
Participants in both carrier groups mentioned the publicity of the BRCA genes as
impacting the family sharing process. On one end, family members’ prior knowledge and
awareness of BRCA made disclosing a BRCA or even a PALB2 result somewhat easier since the
concept was familiar. Celebrity BRCA disclosures, such as Angelina Jolie, and the influx of
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direct-to-consumer genetic tests have been shown to increase awareness and even uptake of
genetic testing (Roberts & Dusetzina, 2017). However, one PALB2 carrier was frustrated that
PALB2 was viewed by others as a “less serious” hereditary cancer gene compared to BRCA. This
participant’s experience is alarming, especially the misconceptions from healthcare providers,
given that PALB2, like BRCA, is considered a highly penetrant cancer gene. On-going
educational efforts are needed to raise awareness about hereditary cancer beyond BRCA among
providers and the public so that lack of understanding does not inhibit family sharing and
medical management (Dean & Rauscher, 2018).
Theme: Confident in Sharing Basics
BRCA and PALB2 participants both reported high confidence in their ability to share their
positive genetic test result with at-risk relatives, which is likely due in part to this sample’s high
educational background. These women were most confident disclosing to their close, female
relatives, which is consistent with previous reports that information is more often communicated
to female relatives (Cheung et al., 2010; Elrick et al., 2017; Etchegary et al., 2013; Kardashian et
al., 2012; MacDonald et al., 2007; Patenaude et al., 2006; Vadaparampil et al., 2012). Difficulty
or uncertainty when responding to relatives’ questions diminished participants’ perceived ability
to share effectively. This finding suggests that highly educated BRCA and PALB2 carriers feel
confident disclosing basic information about their result to relatives, but may benefit from having
resources and contact information for genetics professionals on-hand when sharing. Individuals
need to feel prepared in order for familial disclosures to occur and those that have more
knowledge may feel more comfortable (Cheung et al., 2010; Dean & Rauscher, 2018).

35

Theme: Informational Resources Boost Self-efficacy
Most participants were at least provided some written information about their specific
gene and the associated cancer risks from their provider (frequently a genetic counselor), but not
all received resources related to or to assist with the family sharing process. Several women in
the PALB2 carrier group found that the family sharing letter from their provider was especially
helpful in disseminating information to at-risk relatives. The use of family sharing letters as a
patient resource has become standard practice when heritable genetic risks are identified
(Dheensa, Lucassen, & Fenwick, 2018). Providers did not consistently offer participants in either
group family sharing letters, so it is difficult to determine whether or not the utility of the letter
was specific to the PALB2 group. It is possible that PALB2 carriers found the family sharing
letter more helpful given that there is less information and awareness regarding the PALB2 gene
compared to BRCA1 and BRCA2.
BRCA and PALB2 carriers suggested that a handout explaining the significance of family
sharing, tips for how to share, and even a short script of what to say would be helpful when
disclosing to relatives. Kardashian et al. (2012) designed an educational sharing risk information
tool (ShaRIT), consisting of genetic information along with family resources (including a letter
to family members, FAQ sheet, contact information for providers, and support websites and
brochures) that was well-received by participants. A similar web-based educational aid
developed by Katapodi et al. (2018), called the Family Gene Toolkit, was well-received during
focus groups. Based on participants’ responses, interventions like these could be effective at
increasing confidence with sharing and the likelihood of disclosures. None of these included a
script of what to say to relatives, so that may be a valuable addition. An example family sharing
script can be found in Appendix C.
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Theme: Knowing What to Share and How to Share
The participants in both the BRCA and PALB2 carrier groups demonstrated a clear
understanding of which family members were ‘at-risk,’ what risk information was important to
share, and how they might go about sharing, though this is not always the case (Blandy et al.,
2003; Daly et al., 2016). This finding is likely related to higher education levels among our
sample and consequently greater understanding of relevant information to share. Conversations
with family members focused on the cancer gene involved, associated cancer risks, heritability,
and availability of genetic testing and risk management. The associated cancer risks reported by
the PALB2 carriers varied slightly in terms of ovarian cancer, likely due to changes in the
scientific community’s understanding of PALB2-associated risks over time (Metcalfe, Akbari,
Narod, & Lerner-Ellis, 2017). This highlights the importance of on-going communication with
patients or finding ways for patients to receive updated information related to their gene
mutation.
Theme: Important When Risks Are High, Actionable and Relative is Prepared
The belief that family sharing is highly important was a facilitator for both BRCA and
PALB2 carriers. Multiple participants in each group felt that family sharing was less important in
certain situations, for instance if they expected that family members would react poorly to the
news. This observation relates back to anticipated negative emotional reactions from relatives
and concerns that certain family members may not be prepared to learn about possible risks. The
Disclosure Decision-Making Model explores how individuals assess recipients when making
disclosures, and in the context of BRCA has demonstrated an association between perceived
readiness of relatives and likelihood of family sharing (Dean & Rauscher, 2018; Greene, 2009).
Participants who experienced a negative reaction from a relative after sharing said they would
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still have shared despite the outcome, which suggests that participants feel sharing is more
important than the perceived duty to protect relatives from emotionally troublesome information.
The importance of sharing was also modified by the gene penetrance, associated risks,
and availability of follow-up care. Participants expressed that sharing was more important when
the cancer risks were high and more certain, and if relative’s had the ability to consider riskmanagement strategies. Uncertainty regarding VUS test results has been shown to negatively
impact family sharing due to the complexity of the result and lower perceived utility of this
information for relatives (Hughes et al., 2002; Patenaude et al., 2006; Vadaparampil et al., 2012).
Participants in this study were all gene positive, but may similarly see genetic test results as less
relevant to family members when there is limited or evolving knowledge of gene penetrance,
cancer risks, and recommended follow-up care. In some cases, this led participants to feel
sharing was more important for at-risk female relatives rather than male relatives, given the
breast and ovarian (when applicable) cancer risks. Participants admitted feeling that sharing was
less important for older relatives, given the lower likelihood of pursuing genetic testing or
follow-up care. These gender and age tendencies with sharing have been reported in the literature
before (Dean & Rauscher, 2018; Finlay et al., 2008; Patenaude et al., 2006).
Theme: High Rates of Family Sharing and Intention to Share
Consistent with the literature on BRCA carriers, this sample of women with BRCA
variants and even women with PALB2 variants showed high rates of family sharing, frequently
disclosing their result to immediate family members and variably notifying more extended
relatives (Blandy et al., 2003; Daly et al., 2016; Elrick et al., 2017; Fehniger et al., 2013; Finlay
et al., 2008; Hughes et al., 2002; Kardashian et al., 2012; Katapodi et al., 2013; MacDonald et
al., 2007; McGivern et al., 2004; Ricker et al., 2018). Participants managed to inform the
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majority of first-, second-, and third-degree relatives at least indirectly through other family
members. Both groups were highly satisfied with their decision to share their positive genetic
test result, but were less impressed with their family members’ follow-up. It has been welldocumented that rates of genetic testing among at-risk relatives are low and interventions are
urgently needed to improve family follow-up (Blandy et al., 2003; Katapodi et al., 2017;
Lieberman et al., 2018). Fortunately, participants were not deterred from sharing due to low rates
of genetic testing among family members.
Participants in both groups usually did not discuss their result with young children
because they anticipated a lack of understanding and utility of the information. This finding is
appropriate given that genetic testing for adult-onset hereditary cancer syndromes is not
recommended for minors and medical management would likely not change until around age 2530 (Caga-anan, Smith, Sharp, & Lantos, 2012; Kesserwan, Friedman Ross, Bradbury, & Nichols,
2016; National Comprehensive Cancer Network, 2018). These women intended to wait until
their child reached a certain age, point of maturity, or readiness, which is a common approach
taken by other women in this type of situation (Hamilton et al., 2005; Patenaude et al., 2006).
Study Limitations
There are several strengths of this study to acknowledge. To start, this study is one of the
first to compare family sharing behaviors among BRCA and PALB2 carriers. Participants were
required to provide documentation of a BRCA1, BRCA2, or PALB2 pathogenic variant, so we did
not need to rely on a self-reported carrier status. Additionally, the sample was diverse with
regard to gene status, which enabled greater variety and comparison of interview responses.
Although participants were primarily white, highly educated, and privately insured, this sample
was representative of the population traditionally accessing genetic services and, thus, most
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likely to face the decision to share (Armstrong, Micco, Carney, Stopfer, & Putt, 2005; Cragun et
al., 2017). Extra interviews for each carrier group were scheduled to ensure the target sample
size would be reached, which ultimately allowed us to include a greater number of participants in
this study. After coding the initial ten interviews for each carrier group and identifying themes,
the additional eight BRCA and three PALB2 interviews were completed and analyzed to ensure
that major barriers and facilitators related to family sharing had been captured.
Despite these strengths, this study does have several limitations. Participants were
selected from a highly motivated population of women who are part of a cancer registry and
willing to participate in research, which may have introduced sampling bias despite attempts to
purposively select those who did not share with all relatives and those from underserved
ethnic/racial groups. In terms of generalizability of these findings, it should be noted that
perceived barriers and facilitators may differ among those who indicated willingness to
participate and those who did not, especially given the high rates of sharing reported in this
sample. Furthermore, there may be barriers and facilitators unique to younger generations, as
well as minority populations and lower socioeconomic status groups with historically lower rates
of family sharing, that could not be captured with this sample (Cheung et al., 2010; Etchegary et
al., 2013; Fehniger et al., 2013).
The current study relied solely on self-reported family sharing behaviors, so true rates of
sharing may differ from the self-reported rates. Because the outcome or quality of participants’
communication was beyond the scope of this study, we did not confirm family members’
reactions or what information they were told. Nevertheless, we were able to infer some
participant misconceptions about PALB2-associated cancer risks that may have been
communicated from the interviews. The time elapsed between genetic testing and disclosure was
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not assessed, though this may be an important factor to consider in future studies related to
family sharing.
Practice Implications
Current findings indicate that health care professionals play an important role in
facilitating the family sharing process across both carrier groups (Black et al., 2013). Studies
have found, though, that variability among providers and clinical sites makes it difficult to create
a standardized protocol for addressing family sharing (D’ Audiffret Van Haecke & de
Montgolfier, 2016). It has been suggested that more time should be devoted to this topic during
the post-test counseling visit and even afterwards via follow-up correspondence (D’ Audiffret
Van Haecke & de Montgolfier, 2016). During these conversations, it would be beneficial to
clarify at-risk relatives and discuss patients’ beliefs about family sharing in order to identify
motivations and address any barriers (Gallo, Angst, & Knafl, 2009). Based on the current
findings, we would expect similar, but tailored interventions to be successful at improving rates
of family sharing for both BRCA and PALB2 carriers.
Being well-supported and -informed throughout the family sharing process has been
shown to positively impact the experience of disclosing genetic test results (Lafrenière et al.,
2013). Providers should offer patients resources that explain why sharing is important and
contain key talking points, tips for how to share, and contact information for genetics
professionals to reduce uncertainty and build confidence (Mendes, Paneque, Sousa, Clarke, &
Sequeiros, 2016). Family sharing letters and other types of educational aids are acceptable,
effective reminders to share and even remind family members to follow-up (Mendes et al.,
2016). Given PALB2 carriers’ high endorsement of family sharing letters, it may be particularly
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helpful to offer these resources to carriers of less common gene mutations. Figure 3 depicts how
these practice implications can be incorporated into the family sharing process.

Figure 3. Practice Implications for Providers Flowchart.

Research Recommendations
Additional research is needed regarding family sharing outside the setting of high-risk
hereditary cancer syndromes, such as Hereditary Breast and Ovarian Cancer syndrome and
Lynch syndrome, to include other highly and moderately penetrant cancer genes. Research
efforts should further examine disclosure behaviors in understudied, minority groups who may
experience unique barriers and facilitators that require tailored interventions. Future studies
should assess the role of providers, the utility of resources, and patients’ efficacy in
communicating genetic risk information to relatives in order to develop effective interventions to
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improve rates and quality of family sharing, overcome age and gender discrepancies with
sharing, and increase follow-up among at-risk relatives.
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Conclusions
The Integrated Behavioral Model (IBM) provides a highly relevant framework for
identifying issues related to family sharing of genetic risk information and developing
appropriate and effective interventions. Current findings suggest that women with pathogenic
BRCA variants and women with pathogenic PALB2 variants experience similar attitudes,
normative influences, and personal control beliefs when disclosing positive genetic test results to
at-risk relatives, thus may benefit from similar, but tailored interventions to improve rates of
sharing. Based on participant responses, future interventions should involve a discussion of
patients’ beliefs about sharing with healthcare providers to strengthen motivations and address
other barriers and provision of informational resources to increase confidence and knowledge. It
is crucial that these family sharing resources clearly specify which relatives should be informed,
why sharing is important, and how at-risk relatives may benefit.
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Appendix A:
Interview Guide Questions by Integrated Behavioral Model Construct
Experiential attitude





How did/do you feel about the idea of sharing your genetic test result with family members?
What would be good about sharing this information?
What would be bad about sharing this information?
Did you struggle emotionally to tell them?

Instrumental attitude






Were there any negative effects of sharing?
Were there any benefits of sharing?
Do you think there are benefits of sharing your result?
What would be the negative effects of sharing your result?
How likely do you think sharing your result would lead to these positive or negative
outcomes?

Normative influence










Please give me examples of how family members reacted when you told them your genetic
test result.
What did these individuals say to you after they heard your result?
Who supported you sharing your result?
Was anyone against you sharing your result?
Did you fear their reaction?
Do you feel they would be against you sharing?
Who would support you sharing your result?
Who might be against you sharing your result?
Did some relatives not want to hear about your result?

Perceived control and environmental constraints





What made it easy for you to share your genetic test result?
Are you not close with any of your family members?
Explain for me if you feel there is anything that could make it easier for you to share your
genetic test result with family members.
Were you not able to get a hold of certain relatives?
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Did you simply not have the time to share your result?
Was anything going on in your life or your family members’ lives that influenced your
decision?

Self-efficacy











On a scale of 1-10, how confident were you in talking to your family members?
Why not a ___ [lower value]?
Which family members did you feel most confident sharing this information with?
How certain are you that you can share your result with family members if you wanted?
Which family members do you feel most confident sharing your result with?
Would a brief family sharing letter provided to you be helpful in sharing this information?
Would any other assistance by a professional be helpful?
If available, would you prefer for a healthcare professional to share your genetic test result
with family members, with your permission?
Do you have any suggestions for how other patients can share their genetic test result with
their family members?
What type of resources do you think could be helpful?

Knowledge and skills to perform behavior








Describe for me how and what information you gave these family members when letting
them know about your genetic test result.
What did you say when telling them your result/did you tell certain family members
differently versus others?
How did you inform them of your result?
Were you not given enough information?
Are you not sure how to talk to your family members?
If you have not shared with family but plan to, what information would you share with them?
How might you go about sharing your result?

Salience of behavior







When someone tests positive for a gene mutation associated with hereditary cancer [or has a
VUS], on a scale of 1-10 how important is sharing those genetic test results with family
members?
Please describe why you feel this way?
What would make it a ___ [insert higher value]?
Was it because you wanted them to consider having genetic testing themselves?
Is it important for family members to have genetic testing? Why or why not?
Were you not encouraged to share your result with family members?

Intention or decision to perform behavior
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Apart from healthcare professional(s), did you talk to anyone else about your genetic test
result, meaning did you tell anyone else that you had genetic testing and/or tell them about
your genetic test result?
Did you tell friends, family members, coworkers, etc.?
[If you told family members]: Which family members did you talk to about your genetic test
result; for example, your mother, sister, or uncle?
How satisfied are you with your decision to share your result?
Do you intend to share your result with family members in the future? Why or why not?
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Appendix B:
Final Codebook
Description

Code
ATT_negative
ATT_positive
ATT_mixed

Attitudes
Emotional response to the idea of
family sharing, beliefs about the
outcomes of family sharing, and
outcomes of family sharing.

ATT_indifferent
ATT_expected
ATT_not expected
ATT_fam positive
ATT_fam negative
ATT_fam other

NORM_supportive
Normative Influence
Social pressure one feels to share or
not share results with
family. Includes pressure from nonfamily members (e.g. healthcare
providers, friends, etc.).

Code Description
participant's negative attitude
about sharing
participant's positive attitude
about sharing
participant's mixed positive
and negative attitude about
sharing
participant's indifferent
attitude about sharing
family member attitude was
expected
family member attitude was
not expected
family reacted positively to
sharing
family reacted negatively to
sharing
family reacted neither
positively or negatively to
sharing
supportive of sharing

NORM_not
supportive

not supportive of sharing

NORM_mixed

mixed about sharing

PC_easy

things making it easy to share

Perceived Control/Environmental
Constraints
Perception of the degree to which
various environmental factors make PC_difficult
it easy or difficult to share result with
family members.
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things making it difficult to
share

Description

Code
SE_confident
SE_mixed

Self-Efficacy
Belief in one's ability and
effectiveness in sharing results with
family.

SE_not confident
SE_resources
SE_advice

Knowledge/Skills
Possessing the knowledge and skills
to communicate results to family.

KNOW_how to
share
KNOW_information
SAL_high

Salience
Belief that family sharing is
important.

SAL_low
SAL_mixed

DEC_shared family
DEC_not shared
DEC_shared
conditionally
Decision/Intention
Indication of an individual's
readiness or decision to share results
with family.

DEC_intend to share
DEC_satisfaction
DEC_shared nonfamily
DEC_not shared
non-family
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Code Description
confident can share with
family
confident can share with
certain family members
not confident can share with
family
things that would help with
family sharing
advice for others in family
sharing
knowledge of how to
communicate risk
information
knowledge of information to
communicate to others
it is important to share with
family
it is not important to share
with family
it may be important to share
with some family members
but not others
shared with family
have not shared with family
shared with family under
certain
conditions/circumstances
intend to share with family in
the future
satisfaction regarding
decision to share
shared with non-family
members, such as friends or
co-workers
not shared with non-family
members

Appendix C:
Family Sharing Sample Script
Hi [relative’s name]. Thank you for taking time to talk with me today. I have some news
to share with you that is hard for me to say and might be hard for you to hear. You are someone
that I love and care about, so I think this is important information for you to know. I did a blood
test that found I have a change in my DNA that increases my chance to get certain cancers. This
change is in the part of my DNA called [gene], which increases the chance for [associated cancer
types] cancers. This result helps explain why I got my [cancer type] cancer. This change does not
mean I will for sure get cancer/another cancer. But, now that I know I have a higher chance, I
have decided to do more screenings/surgery to catch a future cancer early/reduce my chance of
cancer as much as possible.
This DNA change is something that can run in families, meaning that you and other
relatives might have it, too. Both guys and girls in the family could have it and have a higher
chance for the cancers I mentioned. We think it’s coming from mom/dad’s side of the family,
which could explain the cancers on that side. I know this might be scary to hear, but thankfully
there is something you can do. You should talk to a genetic counselor about genetic testing.
Genetic testing can tell if you have the same DNA change as me and if you need to worry about
higher cancer risks. If you have the change, your doctors will follow you more closely. If you
don’t have the change, then you won’t have to worry or do anything extra. I really hope you will
consider genetic testing. I don’t want you to get cancer like I did, especially when there is
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something we can do to stop it. Just know that I want to help you do whatever you can to protect
your health.
I have some information for you that I got from my genetic counselor/provider. It has
everything I just told you and some contact information for professionals if you have more
questions. I know that was a lot to hear, but I thought it was important for you to know. What are
you thinking?
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Appendix D:
Informed Consent Form
Institutional Review Board
Informed Consent Document for Research
Principal Investigator: Tuya Pal, M.D.
Revision Date: 11/15/18
Study Title: GeneCARE: A Follow-Up Package for Gene-Based Care for Women At-Risk for
Inherited Cancer
Institution/Hospital: Vanderbilt University Medical Center
This informed consent applies to adult women living in the United States who are at-risk for
hereditary cancer with a documented pathogenic mutation or variant of uncertain significance
(VUS) in a gene associated with hereditary cancer.
Name of participant: _____________________________________________ Age: ___________
The following is provided to you to tell you about this research study. Please read this form with
care and ask any questions you may have about this study. Your questions will be answered.
Also, you are given the opportunity to download a copy of this informed consent form for your
records.
You do not have to be in this research study. You can stop being in this study at any time. If we
learn something new that may affect the risks or benefits of this study, you will be told so that
you can decide whether or not you still want to be in this study. If you are a Vanderbilt patient,
your medical record may contain a note saying you are in a research study. Anyone you
authorize to receive your medical record will also get this note.
1. What is the purpose of this study?
You are being asked to take part in this new research study (conducted through
Vanderbilt University Medical Center and in partnership with collaborators from the
University of South Florida) that is enrolling adult women who are at-risk for hereditary
cancer and have a known pathogenic mutation or VUS in a gene associated with
hereditary cancer. The purpose of this study is to better understand access to follow-up
care recommended by a healthcare professional after genetic testing and how patients go
about sharing their genetic test results with family members. About 500 people will take
part in this study.
2. What will happen and how long will you be in the study?
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If you agree to be in this study, we will ask you to take an online survey. This will take
about 10-15 minutes of your time. At the end of the survey, we will ask if you would be
willing to take part at a later time in an in-depth phone interview that will be recorded.
If you agree to take part in the phone interview and are selected for this second part of
the study, we will schedule a later time and date for your interview. At that time, a
member of the study team from Vanderbilt or the University of South Florida will call
you and ask you more questions over the phone. This phone interview will be recorded
and will take about 30-60 minutes of your time.
After the phone interview, the study team from Vanderbilt may contact you to ask you to
contact up to five of your blood-related adult family members (18 years of age or older)
to ask their permission to share their contact information with the study team so they may
receive information about inherited cancer. You will need to contact these family
members and ask for permission to share their contact information with the study team.
Once we receive this information and permission to contact, we will mail or phone them
to provide general information about hereditary cancer services and where they can get
more information about inherited cancer. We will also provide them with contact
information of the study team if they want more information.
3. Costs to you if you take part in this study:
There is no cost to you for taking part in this study.
4. Side effects and risks that you can expect if you take part in this study:
Questionnaire and Interview:
This study only involves a brief online survey (all participants), and a phone interview
and follow-up contact (up to 100 selected participants), therefore the risk of injury or
personal harm due to this study is very low. There is always the chance that some of your
private information may be accidentally released. The study team will do everything
possible to reduce these risks. All study staff have received required training on how to
keep information private.
Family Contact Information:
If you are one of the 100 participants selected for the second part of this study, we will
ask you to identify up to five blood-related adult family members and share their contact
information with us after getting their permission. Strong steps will be taken to keep this
information private, and it will not be used for any purpose outside of this study. You
have the right to not provide information about your family for this research. We
understand that family members may react differently towards sharing this type of
information for the purposes of research.
5. Risks that are not known:
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There may be risks that we do not know about at this time. If we find any other risks we
will let participants know.
6. Payment in case you are injured because of this research study:
If it is determined by Vanderbilt and the Investigator that an injury occurred as a direct
result of the tests or treatments that are done for research, then you and/or your insurance
will not have to pay for the cost of immediate medical care provided at Vanderbilt to treat
the injury. There are no plans for Vanderbilt to pay for any injury caused by the usual
care you would normally receive for treating any illness or the costs of any additional
care. There are no plans for Vanderbilt to give you money for the injury.
7. Good effects that might result from this study:
a) The benefits to science and humankind that might result from this study: This study
may help to increase our overall knowledge of access to follow-up care recommended by
healthcare professionals after genetic testing and how patients share genetic test results
with family members. This knowledge can help to develop strategies to improve followup care and family sharing among those at risk for inherited cancer.
b) The benefits you might get from being in this study: None.
8. Other treatments you could get if you decide not to be in this study:
This is not a treatment study. You may decide not to be in the study and nothing about
your healthcare will change.
9. Payments for your time spent taking part in this study:
If you enroll online and complete the online survey, you will receive a $10 gift card. If
you are selected for and complete the in-depth phone interview, you will receive a $50
gift card to reimburse you for your time.
10. Reasons why the study doctor may take you out of this study:
You may be taken out of the study if you request it. If you are taken out of the study for
any other reason, you will be told why.
11. What will happen if you decide to stop being in this study?
Being in this study is your choice. You can choose to stop being in this study at any time.
Any routine care you receive will not change if you choose to participate or if you choose
not to participate in this study. If we learn something new that may affect the risks or
benefits of this study, you will be told so that you can decide whether or not you still
want to be in this study. If you decide to stop being part of the study, you should contact
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the study team. At that time, we will stop gathering information about you, however the
data that is already part of the study will be kept.
12. Who to call for any questions or in case you are injured:
If you should have any questions about this research study or if you feel you have been
hurt by being a part of this study, please feel free to contact Tuya Pal, M.D. C/O the
GENECARE Study Team at (615) 875-2444.
For additional information about giving consent or your rights as a person in this study, to
discuss problems, concerns, and questions, or to offer input, please feel free to call the
Vanderbilt University Institutional Review Board Office at (615) 322-2918 or toll free at
(866) 224-8273.
13. Confidentiality:
If you agree to take part in this study, all information collected by Vanderbilt University
Medical Center and the University of South Florida during the study will be kept strictly
confidential. In accordance with federal law, we will keep the study records private by
storing them in a locked area or on a password-protected computer. Your identifying
information, such as your name and contact details, will be kept separately in a secure
location, so that only the study team can access it. When we use data collected in the
study, the information that identifies you will not be used. Instead, we will give you a
study identification number that no one else can use to identify you. Your name or other
information that would allow someone outside the study to identify you will never be
used in study publications or reports. Your study record will be kept separately from your
regular medical record and insurers will not have access to your study records. If
insurance companies, employers, or others obtain genetic information about you from
this research, it has the potential to affect your insurability or employability. This is why
we will do our best to ensure that privacy of all identifiable study records will be
protected to the full extent provided by law.
Vanderbilt may share your information, without identifiers, to others or use it for other
research projects not listed in this form. Vanderbilt, Dr. Pal, and her staff will comply
with any and all laws regarding the privacy of such information. There are no plans to
pay you for the use or transfer of this de-identified information.
Because this study is funded by the National Institutes of Health (NIH), it is conducted
under a Certificate of Confidentiality. This Certificate keeps us from sharing your
identifiable sensitive information (which is information gathered during the course of
research that might identify you) gathered for research purposes unless you allow us to do
so. It also keeps us from being forced to release your study information as part of a court,
legislative, administrative or other proceeding.
There are times when the Certificate cannot be used. For example, we cannot refuse to
give information to government agencies that oversee or fund research, such as the NIH,
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Department of Health and Human Services (DHHS) or Food and Drug Administration
(FDA). The Certificate also does not stop us from giving information to local
government agencies, law enforcement personnel or others if we suspect you or someone
else is in danger or if we are required to do so by law.
The Certificate does not keep you from giving out information about yourself and your
treatment in this study. We will allow the release of some study information, such as lab
test results, if you wish us to do so and you give us permission in writing. If you have any
questions, please ask the study doctor or study staff.

14. Authorization to Use/Disclose Protected Health Information:
All efforts, within reason, will be made to keep your protected health information (PHI)
private. PHI is your health information that is, or has been gathered or kept by Vanderbilt
as a result of your healthcare. This includes data gathered for research studies by
Vanderbilt and research collaborators at the University of South Florida that can be
traced back to you. Using or sharing (“disclosure”) such data must follow federal privacy
rules. By signing the consent for this study, you are agreeing (“authorization”) to the uses
and likely sharing of your PHI. If you decide to be in this research study, you are also
agreeing to let the study team use and share your PHI as described below.
As part of the study, Vanderbilt University Medical Center may share questionnaire data,
the results of your study and/or non-study linked genetic results, as well as parts of your
medical record, to the groups named below. These groups may include our research
partners at the University of South Florida, the Federal Government Office for Human
Research Protections and the Vanderbilt University Institutional Review Board. Federal
privacy rules may not apply to these groups; they have their own rules and codes to
assure that all efforts, within reason, will be made to keep your PHI private.
The study results will be kept in your research record for at least six years after the study
is finished. At that time, the research data that has not been put in your medical record
will be destroyed. Any research data that has been put into your medical record will be
kept for an unknown length of time.
Unless told otherwise, your consent to use or share your PHI does not expire. If you
change your mind, we ask that you contact the study team in writing and let them know
that you withdraw your consent. The mailing address is:
GeneCARE Study Team 1500 21st Ave. So., Suite 2810 Vanderbilt University Medical
Center Nashville, TN 37212
At that time, we will stop getting any more data about you. But, the health data we stored
before you withdrew your consent may still be used for reporting and research quality.
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If you decide not to take part in this research study, it will not affect your treatment,
payment, or enrollment in any health plans or affect your ability to get benefits. You will
be given the opportunity to download a copy of this informed consent form for your
records.
STATEMENT BY PERSON AGREEING TO BE IN THIS STUDY
I have read this consent form and the research study has been explained to me. All my
questions have been answered, and I freely and voluntarily choose to take part in this
study.
_______________
Date

_____________________________
Signature of patient/volunteer

Consent obtained by:
_______________
Date

_____________________________
Signature
_____________________________
Printed Name and Title
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___________
Time
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